V CompBrief BY VELARION

Chief Financial Officer and Treasurer · ArriVent BioPharma, Inc. (AVBP)

Winston Kung

Winston Kung, Chief Financial Officer and Treasurer of ArriVent BioPharma, Inc., received total compensation of $3,407,068 for fiscal year 2025. This amount includes a base salary of $492,417, a cash bonus of $246,287, and stock-based compensation of $2,654,364.

A named executive officer of ArriVent BioPharma in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$3,407,068

FY2024: $1,832,573

3rd of 3 named executive officers at ArriVent BioPharma by FY2025 total.

3 named officers on file for ArriVent BioPharma, FY2025

See an example →

What this number hides

The filing gives the total. ArriVent BioPharma’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how ArriVent BioPharma’s whole pay program stands against its peers

  • ArriVent BioPharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AVBP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Free

Get Winston Kung’s full pay file as a PDF — free

More than this page: up to 10 years of Winston’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Winston Kung and every company like it: Velarion Intel, free for 3 days, no card →

Winston Kung compensation by year

ArriVent BioPharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as ArriVent BioPharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$469,602$492,417
Bonus$0$0
Stock awards$0$0
Option awards$1,190,331$2,654,364
Non-equity incentive$158,840$246,287
Pension and deferred compensation$0$0
All other$13,800$14,000
Total$1,832,573$3,407,068

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ArriVent BioPharma, Inc. DEF 14A filed April 28, 2026, accession 0001104659-26-050337, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ArriVent BioPharma, Inc. filed document, accession 0001104659-26-050337. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

$1.8M
$3.4M
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option102,726—$7.76
Option120,000—$27.56

Per the Outstanding Equity Awards at Fiscal Year-End table in ArriVent BioPharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

ArriVent BioPharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Zhengbin (Bing) YaoChief Executive Officer and President$9,374,153
Stuart LutzkerPresident, Research and Development$3,431,717
Winston Kung · this pageChief Financial Officer and Treasurer$3,407,068

Winston Kung's compensation dossier, ArriVent BioPharma

You have read Winston Kung's totals and holdings. The dossier adds each equity grant ArriVent BioPharma disclosed for Winston Kung and ArriVent BioPharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full ArriVent BioPharma compensation record

free company brief
ArriVent BioPharma, Inc. (AVBP) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within ArriVent BioPharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ArriVent BioPharma's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ArriVent BioPharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order AVBP

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Winston Kung's compensation dossier